Cargando…
Reply: Lecanemab: turning point, or status quo? An ethics perspective
Autores principales: | Hardy, John, Mummery, Catherine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10473552/ https://www.ncbi.nlm.nih.gov/pubmed/36995943 http://dx.doi.org/10.1093/brain/awad102 |
Ejemplares similares
-
Reply: Unblinding in the lecanemab trial in Alzheimer’s disease
por: Hardy, John, et al.
Publicado: (2023) -
Lecanemab: A hope in the management of Alzheimer’s disease
por: Thakkar, Nandita, et al.
Publicado: (2023) -
German surgical residency training – quo vadis?
por: Flierl, Michael A
Publicado: (2008) -
A Turning Point for China’s Population: No Child and Long Illness
por: Sun, Wenjie, et al.
Publicado: (2023) -
Reply to Pediatric optic neuritis: Points to ponder
por: Khadse, Rutika, et al.
Publicado: (2017)